Achieve Life Sciences, Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter report. Achieve is a clinical-stage biopharmaceutical company developing cytisinicline for smoking cessation and nicotine addiction; it has no approved products and has not generated product revenue.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $15.8 million | $30.1 million |
| General and administrative expense | $11.4 million | $10.7 million |
| Total operating expenses | $27.3 million | $40.8 million |
| Net loss | $29.8 million | $42.4 million |
| Basic and diluted loss per share | $1.50 | $4.00 |
| Net cash used in operating activities | $24.5 million | $37.6 million |
- Cash and cash equivalents were $15.5 million at year-end, down from $24.8 million. Working capital was negative $3.8 million; accumulated deficit was $165.8 million. Stockholders’ equity was negative $1.4 million.
- Year-end convertible debt had a reported carrying value of $16.7 million. The filing also states that principal amounts due under debt instruments totaled $17.3 million; investors should reconcile these figures with the debt note.
- Operating cash use fell primarily because Phase 3 ORCA-3 and Phase 2 ORCA-V1 trials wound down; NDA-enabling studies and manufacturing/regulatory readiness work partly offset the reduction.
- In February 2024, the company raised approximately $56.2 million net from a registered direct offering and concurrent warrant placement. Management said cash, including these proceeds, was expected to fund current expenses and capital expenditures into the second half of 2025, including potential NDA submission and debt repayment.
Margins are not meaningful because the company reported no product revenue. No formal earnings or revenue guidance was provided.
Material changes and business developments
- Research and development expense declined by about 47% year over year, reflecting trial completion and lower trial activity. General and administrative expense increased about 7%, including higher employee, legal, investor-relations, and commercial-planning costs.
- Both Phase 3 smoking-cessation trials were completed with positive results. In ORCA-2, 12-week treatment produced a 32.6% quit rate in weeks 9–12 versus 7.0% for placebo; in ORCA-3, the comparable rates were 30.3% versus 9.4%. The filing reports no treatment-related serious adverse events in either trial.
- In the Phase 2 ORCA-V1 vaping study, 12-week cytisinicline treatment produced 31.8% cessation in weeks 9–12 versus 15.1% for placebo. This remains an investigational indication.
- After year-end, the company agreed with the FDA that a single open-label long-term safety study, ORCA-OL, would satisfy the additional exposure-data requirement for an NDA submission. The company planned to start the study in Q2 2024 and anticipated submitting an NDA in the first half of 2025, subject to study results and regulatory review.
Outlook, risks and unusual items
- Debt and liquidity: The convertible term loan bears a floating cash-interest component plus 7% annual interest compounded monthly. Although scheduled to mature in December 2024, it may mature as early as August 2024 depending on FDA NDA filing-acceptance milestones. A February 2024 maturity-extension term sheet was non-binding; a definitive extension was not assured. The debt is secured by substantially all company assets except intellectual property.
- Funding and dilution: The company expects continued losses and requires additional capital for development and commercialization. The February 2024 financing substantially increased shares outstanding and included warrants that may add further dilution.
- Development and regulatory risk: Cytisinicline is the company’s sole product candidate. The FDA may request additional studies, and the planned ORCA-OL study could be delayed, produce unfavorable safety findings, or fail to support an NDA.
- Supply and intellectual property: Clinical supply depends on Sopharma, the sole current manufacturer, using plant-derived raw materials sourced outside the United States. The company identifies geopolitical, environmental, manufacturing-quality, and supply-continuity risks. Cytisinicline itself is naturally occurring and not patentable in the United States; protection relies on other intellectual property, exclusivity, and supply arrangements.
- Other items: The company recorded a $0.5 million loss from the increase in fair value of contingent consideration potentially payable to Sopharma upon regulatory approval. There were no material legal proceedings reported. PwC issued an unmodified opinion on the financial statements; management reported effective disclosure controls and internal control over financial reporting. PwC did not audit or opine on internal-control effectiveness.
Investor verification priorities
- Confirm the status and terms of any definitive debt-maturity extension, the amount due, and the effect of the loan’s FDA-related acceleration clauses.
- Review the February 2024 financing’s final share and warrant terms, resulting dilution, and updated cash runway against projected spending and debt obligations.
- Track ORCA-OL enrollment, cumulative long-term exposure totals required by FDA, safety results, and whether the anticipated first-half 2025 NDA timing remains achievable.
- Verify FDA filing and review requirements, including any additional clinical, nonclinical, manufacturing, or impurity-related requests.
- Assess Sopharma supply capacity, FDA inspection readiness, raw-material sourcing resilience, and progress toward additional commercial manufacturing arrangements.